Targeting drug resistance in breast cancer: the potential of miRNA and nanotechnology-driven delivery systems
Open Access
- 12 November 2024
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 6 (24) , 6079-6095
Abstract
This review explores the synergistic administration of miRNA and chemotherapeutic agents to combat drug resistance in breast cancer, emphasizing cutting-edge drug delivery systems and their profound implications for clinical outcomes.Keywords
Funding Information
- Indian Council of Medical Research (EM/Dev/SG/217/1078/2023)
This publication has 158 references indexed in Scilit:
- The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cellsBreast Cancer Research and Treatment, 2010
- Stable knockdown of microRNA in vivo by lentiviral vectorsNature Methods, 2008
- Gene Therapy Using Adeno-Associated Virus VectorsClinical Microbiology Reviews, 2008
- Mechanisms of microRNA deregulation in human cancerCell Cycle, 2008
- Intrinsic Resistance of Tumorigenic Breast Cancer Cells to ChemotherapyJNCI: Journal of the National Cancer Institute, 2008
- Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO OncoproteinCancer Cell, 2007
- Drug Resistance and the Solid Tumor MicroenvironmentJNCI: Journal of the National Cancer Institute, 2007
- The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancerInternational Journal Of Clinical Practice, 2007
- Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cellsCancer Cell, 2006
- Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegansCell, 1993